Telix announces cardinal health for gozellix commercial distribution

Melbourne, australia and indianapolis, april 08, 2025 (globe newswire) -- telix pharmaceuticals limited (asx: tlx, nasdaq: tlx, telix, the company) today announces that it has selected cardinal health, inc. (nyse: cah, cardinal health) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of gozellix® (kit for the preparation of gallium-68 (68ga) gozetotide injection), telix's next-generation psma-pet imaging1 agent for prostate cancer in the united states (u.s.).
CAH Ratings Summary
CAH Quant Ranking